Updated:
NervGen Pharma Corp
NervGen Pharma Corp is a publicly traded clinical-stage biotechnology company developing NVG-291 for spinal cord injury and multiple sclerosis.
NervGen Pharma Corp
NervGen Pharma Corp operates as a publicly traded biotechnology company, not a family office or asset manager. Its focus is the discovery and development of treatments for nerve damage and neurodegenerative conditions. The company is listed on the TSX Venture Exchange (ticker: NGEN) and has not publicly disclosed founding principals or an investment management function. NervGen's primary asset is NVG-291, a therapeutic peptide designed to promote neural repair. The company has conducted preclinical studies in models of spinal cord injury and multiple sclerosis, with early clinical trials dating to 2021. No named venture investors or large-scale institutional holders have been publicly confirmed beyond typical TSX filings. The firm maintains a small team—headcount has not been officially disclosed—and lists a corporate office in Vancouver, Canada. No recent operational events outside standard clinical trial updates have been reported in the last 24 months. The company does not operate philanthropic foundations or investment vehicles. NervGen's structure as a clinical-stage public company is distinct from a family office or private asset manager. Its funding sources include public equity raises and potential partnership deals, with no disclosed permanent capital base or multi-generational wealth origin.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is NervGen Pharma Corp's business model?
NervGen Pharma Corp is a clinical-stage biotechnology company, not an asset manager or family office. It develops therapies for nervous system damage, with a lead candidate NVG-291 targeting spinal cord injury and multiple sclerosis. The firm funds operations through public equity markets and potential licensing deals.
Does NervGen manage capital for any family or institution?
No. NervGen Pharma Corp is a publicly traded company (TSX: NGEN) focused on drug development. It does not operate as a family office, asset manager, or investment firm. Its shareholders include public market investors, not a single family or external allocators.
What is NervGen's track record in clinical trials?
NervGen has advanced NVG-291 into Phase 1 clinical trials, with a Phase 1b/2a study in spinal cord injury initiated in 2021. The company has published preclinical data in peer-reviewed journals, but no regulatory approvals have been secured. The firm's pipeline also includes programs in multiple sclerosis and Alzheimer's disease.
Who founded NervGen Pharma Corp?
NervGen Pharma Corp was founded by a group of scientists and executives including Dr. Jerry Silver, a professor at Case Western Reserve University, and other biotech professionals. The company's executive team is not structured around a single family or personal fortune.
What is NervGen's geographic footprint?
NervGen is headquartered in Vancouver, Canada, with its scientific collaborations spanning North American research centers. The company is listed on the TSX Venture Exchange and does not operate additional investment offices in other regions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: